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Abstract: Bovine mastitis, an infection of the cow’s mammary gland, is frequently caused by
Streptococcus uberis and causes major economic losses in the dairy industry. The intramammary
administration of antibiotics currently remains the predominant preventive and therapeutic measure.
These antimicrobial compounds, of which some are considered critical in human health care, are frequently
applied as dry therapy resulting in their consistent overuse. Therefore, the use of antibiotics in the
dairy sector is being questioned. We here identified two endolysins, i.e., PlySs2 and PlySs9, respectively
derived from Streptococcus suis serotype-2 and -9 prophages, with lytic activity against S. uberis in an
in vitro setting. Both endolysins gave clear lysis zones in spot-on-plate assays and caused a reduction
of the optical density in a turbidity reduction assay. In depth characterization identified PlySs9 as the
more potent endolysin over PlySs2 with a lower MIC value and about one additional log of killing.
PlySs2 and PlySs9 were challenged to a panel of subclinical and clinical S. uberis milk isolates and were
both able to lyse all strains tested. Molecular dissection of these endolysins in catalytic and cell wall
binding subdomains resulted in major loss of killing and binding activity, respectively. Taken together,
we here propose PlySs2 and PlySs9 as candidate compounds to the current antimicrobial arsenal known
against bovine mastitis-causing S. uberis as future add-on or replacement strategy to the currently used
intramammary antibiotics.
Keywords: PlySs2; PlySs9; bacteriophage-derived endolysins; bovine mastitis; dairy industry;
intramammary antibiotics; alternative antimicrobials
1. Introduction
Bovine mastitis, an infection of the cow’s udder, is the most important economic disease affecting
dairy cattle [1,2]. This infection is typically caused by a large variety of microorganisms and has
either a clinical or subclinical outcome. Mastitis is frequently caused by the Gram-positive pathogen
Streptococcus uberis [3–5]. Although good hygiene practices during the milking process diminish
the incidence of streptococcal bovine mastitis, a full eradication proves impossible [6]. Additional
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preventive measures such as vaccination and probiotics have also been proposed [7,8]. Although
these measures lower the infection rate, they do not result in elimination of the disease [9]. Therefore,
antibiotics are still the main preventive and therapeutic tool for bovine mastitis, resulting in overuse
mainly due to their application as dry therapy [10,11]. Several of these formulations contain quinolones,
macrolides and cephalosporines of the third and fourth generation, which are considered critical in
human health care by the World Health Organization [12]. Moreover, antibiotics can persist in milk
and affect the dairy product or starter cultures of e.g., cheese and yoghurt fermentations. Therefore,
the milk of treated animals has to be discarded, resulting in food waste and a negative impact on the
environment [10]. Last but not least, the emerging risk of antibiotic resistance development in the
dairy industry drives the search for alternative and superior solutions [3,13]. With the consumer’s
demand moving towards more sustainable dairy products, the role of antibiotics as a preventive and
therapeutic measure in this sector is increasingly questioned.
The use of bacteriophages (phages) and their lytic enzymes have been proposed as strategies that
may supplement the current antibiotic arsenal [14–18]. Although phage therapy was initially considered
promising, more recent insights revealed several remaining hurdles i.e., unpredictable pharmacokinetics
and -dynamics, large molecular size compared to antibiotics, low tissue penetration, narrow bacterial
specificity, the necessity to replicate in vivo, elevation of the somatic cell count in the cow’s milk and
inactivation of bacteriophage by whey proteins [19–21]. However, phage-derived enzymes such as
tail-spike enzymes (i.e., depolymerases) and endolysins bypass these disadvantages [22,23]. Endolysins,
the most well-studied phage-derived peptidoglycan hydrolases, have been shown to successfully
kill bacteria in vitro, in various animal models and in humans [15,22,24]. Local, topical therapy as
well as single intravenous injections are either recently available on the pharmaceutical market or in
full development, albeit only for human applications [25,26]. Hence, endolysins offer an interesting
potential within the context of veterinary medicine [14,16–18]. More specifically, several endolysins
have already been proposed to target Gram-positive pathogens associated with bovine mastitis [27–31].
In the current study, two endolysins, named PlySs2 and PlySs9 as derivatives from prophages in the
genomes of the porcine pathogen Streptococcus suis, were characterized as potential antimicrobial
compounds against bovine mastitis-causing S. uberis. PlySs2 is known to display broad lytic activity
against several streptococci i.e., Streptococcus equi, Streptococcus agalactiae, Streptococcus dysgalactiae,
Streptococcus pyogenes, Streptococcus sanguinis, Streptococcus pneumoniae and group E streptococci [32–34].
In addition, its lytic activity was confirmed in an animal model showing eradication of S. suis from
murine nasal mucosa with a > 4 log reduction [35]. In contrast, our group is the first to report PlySs9,
but its protein sequence is 96.5% identical to PlySK1249, an endolysin derived from a S. dysgalactiae
prophage [36]. The latter endolysin was able to lyse S. dysgalactiae and S. agalactiae in vitro and its
efficacy and safety were already preclinically evaluated in vivo. Regardless, neither PlySs2 nor PlySs9
have been investigated in depth against bovine mastitis-causing S. uberis. Therefore, we evaluated
the in vitro lytic activity of PlySs2 and PlySs9, as well as their individual subdomains, as potential
therapeutics in the future treatment of bovine mastitis caused by S. uberis.
2. Results
2.1. Properties of PlySs2, PlySs9 and Their Individual Subdomains
PlySs2 is 26.9 kDa in size and has an isoelectric point (pI) of 9.06. It consists of an N-terminal
histidine-dependent amino hydrolase/peptidase (CHAP) catalytic domain and a C-terminal SH3_5
cell-wall binding domain (CBD). The CHAP and SH3_5 subdomains range from position 12–147 and
193–228, respectively, within the PlySs2 amino acid sequence (Figure 1A). PlySs9 is 54.1 kDa in size
and has a pI of 9.08. It consists of one LysM-based CBD and two catalytic domains, an N-terminal
N-acetylmuramoyl-L-alanine amidase and a C-terminal endopeptidase. The amidase subdomain
ranges from position 3–169, the CBD from position 269–315 and the endopeptidase from position
394–485 (Figure 1B).
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Figure 1. Schematic representation of the parental PlySs2 (A) and PlySs9 (B) protein sequences and 
their respective synthesized genes. PlySs2 consists of an N-terminal histidine-dependent amino 
hydrolase/peptidase (CHAP) and a C-terminal SH3_5 cell binding domain (CBD). PlySs9 has a LysM-
based CBD and two catalytic domains; an N-terminal N-acetylmuramoyl-L-alanine amidase and a C-
terminal endopeptidase. Subdomain boundaries regarding cloning into a pBAD24 or pET28a vector 
were selected to correspond to the linker regions such that predicted α-helices and β-sheets were not 
disrupted. To aid in downstream purification, the coding sequence for a polyhistidine tag was 
incorporated into the reverse primers used to amplify subdomain sequences (see also Table 2). 
The mass, pI’s and expression yields of full-length and subdomains for both PlySs2 and PlySs9 
are represented in Table 1. The PlySs9 endopeptidase subdomain was not expressed in a soluble form 
and therefore its further purification and downstream assays could not be performed. The size and 
purity of all proteins were verified by SDS-PAGE (Figure A1).  
Figure 1. Schematic representation of the parental PlySs2 (A) and PlySs9 (B) protein sequences and
their respective synthesized genes. PlySs2 consists of an N-terminal histidine-dependent amino
hydrolase/peptidase (CHAP) and a C-terminal SH3_5 cell binding domain (CBD). PlySs9 has a
LysM-based CBD and two catalytic domains; an N-terminal N-acetylmuramoyl-L-alanine amidase
and a C-terminal endopeptidase. Subdomain boundaries regarding cloning into a pBAD24 or pET28a
vector were selected to correspond to the linker regions such that predicted α-helices and β-sheets were
not disrupted. To aid in downstream purification, the coding sequence for a polyhistidine tag was
incorporated into the reverse primers used to amplify subdomain sequences (see also Table 2).
The mass, pI’s and expression yields of full-length and subdomains for both PlySs2 and PlySs9
are represented in Table 1. The PlySs9 endopeptidase subdomain was not expressed in a soluble form
and therefore its further purification and downstream assays could not be performed. The size and
purity of all proteins were verified by SDS-PAGE (Figure A1).
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Table 1. Molecular size (kDa) and iso-electric point (pI) was calculated from the amino acid composition
for each protein (see section material and methods) of the different proteins expressed and purified.
The expression yield of the PlySs9 endopeptidase subdomain could not be determined, because it was
expressed insolubly.
Protein Molecular Size (kDa) pI Expression Yield (mg/L)
PlySs2 26.9 9.06 0.25
PlySs2 CHAP 17.2 7.10 2.60
PlySs2 SH3_5 10.3 9.57 1.10
PlySs9 54.1 9.08 0.12
PlySs9 Amidase 21.8 6.75 20.0
PlySs9 LysM 12.2 9.84 1.10
PlySs9 Endopeptidase 16.6 6.42 Not determined
2.2. Qualitative Assessment of the Lytic Activity of PlySs2, PlySs9 and Their Catalytic Subdomains
To confirm that expression and purification of both parental endolysins and their catalytic
subdomains resulted in properly folded and active proteins, a spot-on-plate assay was performed with
S. uberis as well as S. suis. The latter pathogen was included as a positive control, since it is the host
of the bacteriophages from which the parental endolysins were derived. PBS buffer without protein
was used as negative control. PlySs2, PlySs9, PlySs2 CHAP and PlySs9 amidase all gave clear lysis
zones on both S. uberis and the positive control, while no lysis was observed in the negative control
(Figure 2). Taken together, the results indicate full-length enzymes and catalytic subdomains were
properly folded.
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 Figure 2. Qualitative spot-on-plate assays of PlySs2, PlySs9, PlySs2 CHAP and PlySs9 amidase on
S. uberis 0140J and S. suis 7-3008-2 after incubation during 18 h at 37 ◦C. S. suis was included as positive
control, phosphate buffered saline (PBS) served as negative control.
2.3. Quantitative Assessment of the Lytic Capacity of PlySs2, PlySs9 and Their Catalytic Subdomains
To quantify the lytic capacity of the parental endolysins and their catalytic subdomains, turbidity
reduction assays (TRAs) and time killing assays (TKAs) were performed on S. uberis (Figures 3 and 4,
respectively). S. suis again served as the positive control, whereas bacteria in PBS again served as
negative controls. For the TRAs, at equimolar concentrations of 0.5 µM (corresponding to 13.45,
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27.05, 8.60 and 10.90 µg/mL for PlySs2, PlySs9, PlySs2 CHAP and PlySs9 amidase, respectively),
PlySs2 and PlySs9 caused a decrease in OD600 (optical density measured at 600 nm) for stationary
phase S. uberis that was similar to the positive control (Figure 3A). The negative controls did not show
a notable decrease in OD600. In contrast, activity was low to negligible for the PlySs2 CHAP and PlySs9
amidase in this assay. The individual catalytic domains did not induce a drop in OD600 in the positive
control either (Figure 3B), although a limited linear decrease in OD600 for the PlySs9 amidase was
observed. Additionally, the observed enzymatic activity of both parental endolysins against S. uberis
was quantified as described [37] and estimated 0.136 (∆OD600/min)/µM with R2 = 0.965 and 0.176
(∆OD600/min)/µM with R2 = 0.983 for PlySs2 and PlySs9, respectively.
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Figure 3. Turbidity reduction assays with 0.5 µM of PlySs2 and PlySs9 (A), and PlySs2 CHAP and
PlySs9 amidase (B) on stationary phase S. uberis 0140J and S. suis 7-3008-2, the latter pathogen being
included as a positive control. Bacteria in PBS served as negative controls.
Additional TKAs were performed to further evaluate the lytic capacity of both PlySs2 and PlySs9
at the same equimolar concentrations as described for the TRAs (Figure 4). PlySs2 lysed 1.09 ± 0.37 log
of S. uberis, PlySs9 lysed 2.54 ± 0.08 log of the same strain (Figure 4A). Comparable or higher lytic
capacities were observed for the positive control, i.e., 1.36 ± 0.25 log for PlySs2 and 3.86 ± 0.06 log
for PlySs9, respectively (Figure 4A). Again, no significant decrease was observed for either PlySs2
CHAP or PlySs9 amidase (Figure 4B). In addition, no reduction in bacterial number for these individual
catalytic domains was observed in the positive control (Figure 4B).
As a third quantitative parameter, the minimal inhibitory concentration (MIC) was determined for
both the parental endolysins and their catalytic domains. The MIC values exceeded 5 µM (corresponding
to 86, 109 and 134.5 µg/mL for PlySs2 CHAP, PlySs9 amidase and PlySs2, respectively), while the
PlySs9 MIC was significantly lower i.e., 0.48 ± 0.16 µM (corresponding to 26.17 ± 8.80 µg/mL). Thus,
only PlySs9 yielded an observable MIC under the concentrations tested.
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for 2 h at 37 ◦C on stationary phase S. uberis 0140J. S. suis 7-3008-2 served as the positive control and
bacteria in PBS were included as negative controls. 106 CFU/mL were challenged with 0.5 µM enzyme.
* indicates p < 0.05, *** indicates p < 0.001 and ‘ns’ indicates non-significant corresponding to a p > 0.05.
2.4. Evaluation of the Pathogen-Binding Capacity of the PlySs2 and PlySs9 Cell-Wall Binding Domains
After Alexa Fluor 555 conjugation to the CBDs of PlySs2 and PlySs9, (e.g., PlySs2 SH3_5 and
PlySs9 LysM, respectively), no binding to S. uberis was observed (Figure 5). In contrast, the CBDs did
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bind to the S. suis positive control (Figure 5). As a confirmation test, two other S. uberis pathogens i.e.,
ATCC 27,958 and ATCC 700,407 were additionally evaluated and again no binding was observed.
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2.5. Evaluation of the Lytic Activity of PlySs2 and PlySs9 against A Panel of Isolated (Sub)Clinical
S. uberis Strains
To extrapolate the activity of PlySs2 and PlySs9 from the S. uberis 0140J reference strain to the
same pathogen but currently occurring in infected dairy cattle, a panel of recently isolated subclinical
and clinical S. uberis was composed and challenged by TRA with both endolysins at 0.5 µM during
1 h. The strains originated from various dairy farms and were freshly isolated from milk samples by
the Milk Control Center of Flanders (Belgium). They were complementary verified by MALDI-TOF
(data not shown) [38]. The reference strain S. uberis ATCC 27,985 was additionally included. All strains
challenged were susceptible to both PlySs2 and PlySs9 as demonstrated by a reduction in the OD600
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(Figure 6). S. uberis 0140J incubated in PBS served as the negative control. The observed reduction in
OD600 was again the highest for PlySs9 on all strains challenged (Figure 6).
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the references S. uberis 0140J and ATCC 27,958 after 1 h incubation at 37 ◦C with 0.5 µM of PlySs2 and
PlySs9. S. uberis 0140J in PBS served as the negative control (NEG CTRL).
3. Discussion
Bovine mastitis is the most common production disease in the dairy industry and is frequently
caused by the udder pathogen S. uberis [13]. Several preventive, prophylactic and therapeutic measures
have been proposed to combat this infectious disease, but antibiotics currently remain the standard
antimicrobial preventive and therapeutic treatment [6,9]. This systematic (over)use of antibiotics in the
dairy sector is being questioned and as such, endolysins have been proposed as either replacement or
add-on strategy [14,16,18]. We here characterized two endolysins, i.e., PlySs2 and PlySs9, with muralytic
activity against bovine mastitis-causing S. uberis. Both endolysins showed activity against all strains
of a panel consisting of clinical and subclinical bovine S. uberis isolates. In-depth characterization
identified PlySs9 over PlySs2 as the more potent endolysin towards S. uberis, showing the lowest MIC
value and an additional log of microbial killing capacity.
The spot-on-plate assay, TRA, TKA and determination of the MIC are four commonly used
methods to demonstrate antimicrobial activity of endolysins [31,33,35,39]. However, these assays
should be regarded complementary and are not directly comparable to each other [39]. A TKA is a
direct measure of bacterial cell death, whereas a TRA is an indirect assay measuring a loss of turbidity
in a bacterial solution, which can be inferred as corresponding to bacterial death [37]. However,
the loss of turbidity relies on the light scattering phenomenon, which itself can be affected by osmotic
pressure within the bacterial cell, buffer components and contributions of proteins, nucleic acids,
cell wall fragments and capsule [37]. Concerning determination of the MIC, it should be noted
that endolysins are enzymes characterized by a half-life and limited turn-over. When bacteria are
challenged upon determination of the MIC, the enzyme can already be used or inactivated before all
bacteria are killed. Consequently, the remaining bacteria will grow and a MIC cannot be observed.
As such, endolysins can show very promising results in a spot-on-plate assay, TRA or TKA, but no
MIC is observed. In our results, this was present for the full-length PlySs2 endolysin. Out of the
complementary assays discussed, the spot-on-plate assay is by far the most sensitive, because the
endolysin is undiluted and allowed to act on the bacterial target for 18 h. These bacteria are embedded
in a nutrient-lacking agar and can therefore not grow. As a result, enzymes that often show little or
no activity if challenged by TRA, TKA or MIC will show activity in the spot-on-plate assay given the
higher sensitivity of this method. The presence of a clearing zone in the spot-on-plate assay combined
with the fact that the enzyme was expressed as a soluble protein, is proof of proper folding. Therefore,
the observation that the PlySs2 CHAP and PlySs9 amidase showed a lytic zone in the spot-on-plate
assay, but deficient activity in the TRA, TKA and MIC assay, is not a contradictory finding but rather
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additionally underscores the importance of the CBD in binding the bacterial surface for these catalytic
domains. However, it should also be noticed that the spot-on-plate assay has its limits. Diffusional
differences in agarose are different for each endolysin and the size of the clearing zone is highly
dependent on the molecular weight. Therefore, we here regarded the spot-on-plate assay a qualitative
assay, rather than a quantitative method.
Molecular dissection of PlySs2 and PlySs9 into their separate catalytic domains and CBDs identified
the catalytic subdomains with deficient lytic activity towards S. uberis compared to their parental
counterparts. This finding corroborates the general observation on the activity of individual endolysin
subdomains, i.e., catalytic subdomains often lack activity without their corresponding CBDs [22,33].
Nevertheless, notable exceptions to this general exist such as the endopeptidase domains of the phage
endolysins LysK and PlyGBS [40,41]. These latter mentioned catalytic subdomains not only possess
activity, but even have improved activity compared to their respective full-length endolysin. In this
context, it can be noted that a limited linear reduction in OD600 was observed for PlySs9 amidase
in the S. suis positive control. Nevertheless, our data suggest proper folding of these individual
catalytic subdomains. As already discussed, lysis was observed in an agar-based assay after close
contact for 18 h, whereas the other assays performed in solution for only 1–2 h did not reveal any
significant activity. Our data therefore corroborate an earlier report that shows the importance of the
corresponding CBD for full lytic activity of PlySs2 [33]. Comparing this deficient muralytic activity
of the catalytic subdomains with that of the parental endolysins, our data overall suggest that the
presence of CBDs is required for demonstration of full muralytic activity of PlySs2 CHAP and PlySs9
amidase. Still, no binding of the Alexa Fluor-conjugated CBDs was observed for S. uberis, although
both CBDs did bind the S. suis positive control. Our findings for S. uberis resemble similar to studies
with PlySs2 and S. aureus, in which the PlySs2 SH3_5 failed to bind the staphylococcal surface, yet the
full-length enzyme retained high lytic activity toward S. aureus [33]. We suggest that the presence of the
catalytic subdomains most likely is a necessity for optimal binding to the bacterial cell wall of S. uberis.
Notwithstanding the observed deficient activity of the individual subdomains, all subdomains
had improved expression and purification yields compared to their respective parental counterparts,
with the exception of PlySs9 endopeptidase that was expressed insolubly. Moreover, these individual
subdomains were properly folded independently as was observed by spot-on-plate for the catalytic
subdomains and by binding to S. suis for the CBDs. Therefore, these subdomains are amenable to
engineering approaches to create chimeric constructs that may have improved characteristics compared
to their wild type full-length endolysins. Such engineering efforts can be facilitated by recently
introduced high-throughput assembly methods for chimeric endolysins [42].
In conclusion, PlySs2 and PlySs9 both have in vitro muralytic activity against a range of clinical
and subclinical bovine mastitis S. uberis strains. In depth characterization further substantiated PlySs9
as the more potent endolysin, killing one additional log and showing a lower MIC than PlySs2.
Additional molecular dissection of both endolysins showed that the individual subdomains, i.e., PlySs9
amidase, PlySs9 LysM, PlySs2 CHAP and PlySs2 SH3_5, have deficient killing and binding activity
compared to their respective parental endolysin. Taken together, our data warrant the exploration of
PlySs2 and PlySs9 as well as future engineering of their subdomains as candidate novel antimicrobial
compounds against bovine Gram-positive mastitis-causing S. uberis.
4. Materials and Methods
4.1. Bacterial Strains and Culture Conditions
S. uberis ATCC BAA-854, also known as S. uberis 0140J, and S. suis 7-3008-2 (clinical isolate)
were used as reference strains. Two other S. uberis strains, i.e., ATCC 27,958 and ATCC 700,407,
were additionally included. All S. uberis strains used are bovine isolates. Streptococci were grown at
37 ◦C and 5% CO2 in Todd-Hewitt broth with the addition of 1% yeast extract (THY). Initial plasmid
transformation was performed with E. coli DH5α (NEB) and protein expression was executed with
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E. coli BL21 (DE3) (NEB). E. coli were grown in Lysogeny Broth (LB) containing either 100.0 µg/mL
carbenicillin or 50.0 µg/mL kanamycin. Selected plates that were used consisted of the same recipe,
but 5.0 g/L agar was added.
4.2. Structural and Functional Bioinformatics of PlySs2 and PlySs9
PlySs2 and PlySs9 are putative peptidoglycan hydrolases, derived from prophage elements
discovered in S. suis, that belong to serotypes 2 and 9, respectively [32,43]. The endolysin sequences
discovered correspond to the streptococcal bacteriophages phi891591 and phiD12, respectively,
with NCBI GenBank accession numbers AGF87539.1 and AGF87618.1. Analysis of the individual
subdomains, secondary protein structure (α-helices and β-sheets) and three-dimensional structure
were all predicted using Phyre2 [44]. The predicted molecular size and pI reported in Table 1 was
calculated by the pI/Mw tool at ExPASy (https://web.expasy.org/compute_pi).
4.3. Plasmid Construction, DNA Manipulation and Cloning
The PlySs2 and PlySs9 coding sequences were chemically synthesized and codon optimized for
expression in E. coli by ThermoFisher Scientific (Invitrogen Gene Art, Waltham, MA, USA) and a
C-terminal polyhistidine (His6) tag was included for purification purposes. Cloning of the individual
subdomains from the parental endolysins respected the architecture predicted by cleaving in the linker
sequences, not disrupting any predicted α-helices or β-sheets. If needed, a start codon (ATG) or
His6 tag was added to the construct by tail PCR (Table 2 and Figure 1). All constructs were initially
cloned into the pBAD24 vector. The PlySs2 SH3_5 was subcloned into a gateway compatible pET28a
vector using EcoRI and SalI restriction sites. Successful cloning was verified by Sanger sequencing the
constructs (Psomagen, Rockville, MD, USA). The ApE program (University of Utah, Salt Lake City, UT,
USA) was used for DNA sequence analysis and manipulations.
Table 2. Forward and reverse primer sequences and their respective melting temperature (Tm) used to
clone the individual subdomains from the parental endolysins by PCR. The coding sequence of the
polyhistidine tag is underlined.
Subdomain Amplified by PCR Forward Primer Reverse Primer Tm (◦C)
PlySs2 CHAP GAATTCATTATGGCA
CAGGTTGGTAGCGGT
TCTAGATTAATGATGATGATGAT
GATGCTGACGATAGCTTGCTGC
72
PlySs2 SH3_5 GAATTCATTATGAGC
CGTAGCTATCGTGAA
TCTAGATTAATGATGATGATGAT
GATGTTTAAAGGTGCCCCATGC
69
PlySs9 Amidase GAATTCATTATGGGC
AAACATCTGGTGATT
TCTAGATTAATGATGATGAT
GATGATGCTCGGGGTGCCGCTG
68
PlySs9 LysM GAATTCATTATGAAA
GGTCGCACCTACAAA
TCTAGATTAATGATGATGATGAT
GATGGGTCGGAATTGCGGTGGT
68
PlySs9 Endopeptidase GAATTCATTATGAGC
AATCCGTATGGTGGT
GATTTAATCTGTATCAGG 51
4.4. Expression Conditions and Protein Purification
Transformed E. coli BL21 (DE3) were grown as separate 1.5 L cultures in baffled Erlenmeyer
flasks to an OD600 of 0.8–1.0. These cultures were induced with 0.25% L-arabinose (pBAD24) or
1 mM isopropyl β-D-1-thiogalactopyranoside (IPTG, pET28a) and shaken overnight (18 ◦C, 150 rpm).
Next, bacteria were pelleted at 3300 g and resuspended in PBS with 10 mM imidazole and 1 mM
phenylmethylsulfonyl fluoride (PMSF). Cells were sonicated on ice during 15 min (min). Insoluble
cellular debris was removed by centrifugation in a JA-14 fixed angle rotor (Beckman Coulter, Brea, CA,
USA) for 45 min at 25,000 g and 4 ◦C. Ni - NTA chromatography allowed purification of the protein from
the centrifuged supernatant. Proteins were eluted from the nickel resin with PBS containing increasing
concentrations of imidazole (20 mM, 50 mM, 100 mM, 250 mM and 500 mM). Imidazole-eluted fractions
that contained the recombinant protein, as evaluated by SDS-PAGE, were combined and dialyzed for
4 h at 4 ◦C against 5.0 L PBS. All soluble proteins were stable in PBS (pH 7.4), except for the catalytic
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subdomain (i.e., CHAP domain, see results) of PlySs2 which was eluted from the nickel column with
500 mM imidazole in MES-buffer (125 mM MES, pH 6.1) and dialyzed against 3.0 L MES-buffer without
imidazole (250 mM MES, pH 6.1). The cell-wall binding subdomains of both PlySs2 and PlySs9 needed
an additional size exclusion purification step using an S-200 gel filtration column (Äkta, Marlborough,
MA, USA).
4.5. Spot-on-Plate Assays, Turbidity Reduction Assays, Time Killing Assays and Minimal
Inhibitory Concentrations
All assays used purified endolysins or endolysin subdomains. Spot-on-plate assays were performed
by washing an overnight culture (18 h) of S. uberis or S. suis with PBS, followed by dissolving the
bacterial pellet in 10 mL of 0.7% sterile liquid agarose and pouring it in petri dishes. Next, purified
endolysins or PBS (negative control) were spotted on top of the agar and incubated for 18 h at 37 ◦C.
For PlySs2 and PlySs9, 10 µL of a 1 µM enzyme in dialysis buffer was spotted on top of the agar, while
this was 10 µL of a ≥15 µM solution for the catalytic subdomains. TRAs were performed by combining
100 µL of S. uberis or S. suis cells with an equal volume of 1 µM purified enzyme in PBS. Overnight
grown cells were washed with PBS and resuspended with a 1:1 mixture with enzyme to an OD600 = 1.
Next, the OD600 was measured every 15 s at 37 ◦C for 1 h, shaking the 96-well plate between each
measurement. TKAs were performed by diluting an overnight culture, after standardization of the
growth conditions, to 106 colony forming units (CFU)/mL in PBS. A volume of 100 µL of diluted cells was
combined with an equal volume of 1 µM purified enzyme and incubated for 2 h at 37 ◦C. In a next step,
cells were serially diluted and spotted on THY plates. After overnight incubation, CFUs were counted.
TRAs and TKAs were performed in triplicate in two independent experiments. Minimal inhibitory
concentrations (MICs) were determined by diluting an overnight culture in double concentrated THY
to 103 CFU/mL. A 100 µL aliquot of the latter was then combined with an equal volume of aliquots
containing different concentrations of the enzyme in a sterile 96-well plate for an 18 h incubation at
37 ◦C. MIC values were reported in µM to overcome the discrepancy in size of endolysins relative to
antibiotics. MIC determination was performed in three independent experiments.
4.6. Alexa Fluor 555 Labeling and Fluorescence Microscopy
Alexa Fluor 555 labeling was performed according to the manufacturer’s protocol (Alexa Fluor 555
Protein Labelling Kit, ThermoFisher Scientific, Waltham, MA, USA). A 1 M sodium bicarbonate (pH 8.3)
solution was used to reach the desired pH range (7.5–8.5) of the protein solution for optimal conjugation.
Following activation using DMSO, Alexa Fluor 555 was added to the protein solution (2.5 mg/mL) and
incubated for 1 h on a shaker (60–80 rpm) at room temperature. During this incubation, a disposable
PD10 desalting column (GE Healthcare, Chicago, IL, USA) was loaded with resin and equilibrated
with elution buffer. Next, conjugated protein was added to the column and eluted. Fractions that
contained the conjugated protein were collected in 1.5 mL Eppendorf tubes. Subsequently, bacterial
cells in mid-log phase were washed, resuspended in PBS and combined with an equal volume of Alexa
Fluor 555 conjugated PlySs2 SH3_5 or PlySs9 LysM domains. Following 10 min of incubation at room
temperature, cells were again washed with PBS and visualized by fluorescence microscopy (Eclipse
80i, Nikon, Melville, NY, USA). The fluorescence observed was measured at 620 nm as emission
wavelength (540 nm as excitation wavelength).
4.7. Statistical Analysis
Unpaired t-tests were performed using Prism (GraphPad, San Diego, CA, USA) to calculate
p-values. If p < 0.05, the observed difference was considered statistically significant.
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Figure A1. Confirmation by SDS-PAGE of the sizes (Left: protein ladder) and purity (Right: purified 
protein, the reported numbers represent the in silico calculated masses) of the constructs expressed 
and purified: PlySs2 (A), PlySs9 (B), PlySs2 CHAP (C), PlySs2 SH3_5 (D), PlySs9 amidase (E) and 
PlySs9 LysM (F). As PlySs9 endopeptidase (G) was present in the insoluble fraction, it was not 
purified. Gels consisted of 12.5% acrylamide and were stained with Coomassie brilliant blue. 
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